Home
/
Ultragenyx Pharmaceutical Inc.
/
Financials
/
Quarterly
Ultragenyx Pharmaceutical Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Ultragenyx Pharmaceutical Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$159.93M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$166.50M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$139.29M
May 7, 2025
Q3
2025
Sep 30, 2024
$139.49M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$147.03M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$108.83M
May 7, 2025
Q3
2024
Sep 30, 2023
$98.05M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$108.31M
Aug 2, 2024
Q1
2024
Mar 31, 2023
$100.50M
May 3, 2024
Q3
2023
Sep 30, 2022
$90.70M
Nov 3, 2023
Q2
2023
Jun 30, 2022
$89.34M
Aug 4, 2023
Q1
2023
Mar 31, 2022
$79.94M
May 5, 2023
Q3
2022
Sep 30, 2021
$81.65M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$86.98M
Jul 29, 2022
Q1
2022
Mar 31, 2021
$99.40M
May 6, 2022
Q3
2021
Sep 30, 2020
$81.47M
Nov 3, 2021
Q2
2021
Jun 30, 2020
$61.71M
Aug 3, 2021
Q1
2021
Mar 31, 2020
$36.31M
May 5, 2021
Q3
2020
Sep 30, 2019
$25.80M
Oct 27, 2020
Q2
2020
Jun 30, 2019
$24.15M
Jul 30, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$10.68M
May 8, 2018
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($180.41M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($114.95M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($151.08M)
May 7, 2025
Q3
2025
Sep 30, 2024
($133.52M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($131.60M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($170.68M)
May 7, 2025
Q3
2024
Sep 30, 2023
($159.65M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($159.83M)
Aug 2, 2024
Q1
2024
Mar 31, 2023
($163.97M)
May 3, 2024
Q3
2023
Sep 30, 2022
($245.11M)
Nov 3, 2023
Q2
2023
Jun 30, 2022
($158.16M)
Aug 4, 2023
Q1
2023
Mar 31, 2022
($152.32M)
May 5, 2023
Q3
2022
Sep 30, 2021
($73.00M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($122.43M)
Jul 29, 2022
Q1
2022
Mar 31, 2021
($136.14M)
May 6, 2022
Q3
2021
Sep 30, 2020
($68.85M)
Nov 3, 2021
Q2
2021
Jun 30, 2020
$25.32M
Aug 3, 2021
Q1
2021
Mar 31, 2020
($119.03M)
May 5, 2021
Q3
2020
Sep 30, 2019
($112.99M)
Oct 27, 2020
Q2
2020
Jun 30, 2019
($99.17M)
Jul 30, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($170.89M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($107.89M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($142.94M)
May 7, 2025
Q3
2025
Sep 30, 2024
($131.99M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($116.36M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($165.35M)
May 7, 2025
Q3
2024
Sep 30, 2023
($145.10M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($147.96M)
Aug 2, 2024
Q1
2024
Mar 31, 2023
($154.11M)
May 3, 2024
Q3
2023
Sep 30, 2022
($225.07M)
Nov 3, 2023
Q2
2023
Jun 30, 2022
($141.59M)
Aug 4, 2023
Q1
2023
Mar 31, 2022
($136.63M)
May 5, 2023
Q3
2022
Sep 30, 2021
($89.83M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($82.78M)
Jul 29, 2022
Q1
2022
Mar 31, 2021
($106.57M)
May 6, 2022
Q3
2021
Sep 30, 2020
($50.32M)
Nov 3, 2021
Q2
2021
Jun 30, 2020
($63.06M)
Aug 3, 2021
Q1
2021
Mar 31, 2020
($120.67M)
May 5, 2021
Q3
2020
Sep 30, 2019
($118.03M)
Oct 27, 2020
Q2
2020
Jun 30, 2019
($112.47M)
Jul 30, 2020